EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 21 (2014) Parasite, 21 (2014) 61 References
Open Access
Review
Issue
Parasite
Volume 21, 2014
Article Number 61
Number of page(s) 15
DOI https://doi.org/10.1051/parasite/2014059
Published online 18 November 2014
  1. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, Mayer ML, Ma S, Kindrachuk J, Finlay BB, Brinkman FS, Symth GK, Hancock RE, Schofield L. 2012. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Science Translational Medicine, 4, 135ra64. [CrossRef] [PubMed] [Google Scholar]
  2. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Kabwende AL, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D’Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. 2012. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. New England Journal of Medicine, 367, 2284–2295. [CrossRef] [Google Scholar]
  3. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, Mandomando I, Bassat Q, Manaca MN, Leach A, Lievens M, Vekemans J, Dubois MC, Loucq C, Ballou WR, Cohen J, Alonso PL. 2010. Safety, immunogenicity and duration of protection of the RTS, S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One, 5, e13838. [CrossRef] [PubMed] [Google Scholar]
  4. Alving CR. 2002. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine, 20, S56–S64. [CrossRef] [PubMed] [Google Scholar]
  5. Antia M, Herricks T, Rathod PK. 2007. Microfluidic modeling of cell-cell interactions in malaria pathogenesis. PLoS Pathogen, 3, 99. [CrossRef] [Google Scholar]
  6. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature, 505, 50–55. [Google Scholar]
  7. Asami M, Owhashi M, Abe T, Nawa Y. 1991. Susceptibility of multipotent haemopoietic stem cell deficient W/Wv mice to Plasmodium berghei-infection. Immunology and Cell Biology, 69, 355–360. [CrossRef] [PubMed] [Google Scholar]
  8. Babiker HA, Hastings IM, Swedberg G. 2009. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Review of Anti-infective Therapy, 7, 581–593. [CrossRef] [PubMed] [Google Scholar]
  9. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE. 2007. World antimalarial resistance network (WARN)II: in vitro antimalarial drug susceptibility. Malaria Journal, 6, 120. [CrossRef] [PubMed] [Google Scholar]
  10. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ. 2007. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malaria Journal, 6, 122. [CrossRef] [PubMed] [Google Scholar]
  11. Barnes KI, Watkins WM, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends in Parasitology, 24, 127–134. [CrossRef] [PubMed] [Google Scholar]
  12. Barratt G. 2003. Colloidal drug carriers: achievements and perspectives. Cellular and Molecular Life Sciences, 60, 21–37. [CrossRef] [Google Scholar]
  13. Baum J, Papenfuss AT, Mair GR, Janse CJ, Vlachou D, Waters AP, Cowman AF, Crabb BS, de Koning-Ward TF. 2009. Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. Nucleic Acids Research, 37, 3788–3798. [CrossRef] [PubMed] [Google Scholar]
  14. Belyaev NN, Brown DE, Diaz AI, Rae A, Jarra W, Thompson J, Langhorne J, Potocnik AJ. 2010. Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent on IFN-gamma signaling during acute malaria. Nature Immunology, 11, 477–485. [CrossRef] [PubMed] [Google Scholar]
  15. Bessalle R, Gorea A, Shalit I, Metzger JW, Dass C, Desiderio DM, Fridkin M. 1993. Structure-function study of amphiphilic peptides. Journal of Medicinal Chemistry, 36, 1203–1209. [CrossRef] [PubMed] [Google Scholar]
  16. Bjorkman A, Phillips-Howard PA. 1990. The epidemiology of drug-resistant malaria. Transactions of Royal Society Tropical Medicine and Hygiene, 84, 177–180. [CrossRef] [Google Scholar]
  17. Blondelle SE, Houghten RA. 1992. Design of model peptides having potent antimicrobial activities. Biochemistry, 31, 12688–12694. [CrossRef] [PubMed] [Google Scholar]
  18. Bouchaud O, Imbert P, Touze JE, Dodoo AN, Danis M, Legros F. 2009. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malaria Journal, 8, 289. [CrossRef] [PubMed] [Google Scholar]
  19. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. 2005. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Molecular Microbiology, 56, 323–333. [CrossRef] [PubMed] [Google Scholar]
  20. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W, Wernsdorfer WH. 1986. Chemotherapy of malaria. Revised 2nd ed., World Health Organization: Geneva. [Google Scholar]
  21. Catteruccia F, Levashina EA. 2009. RNAi in the malaria vector, Anopheles gambiae. Methods in Molecular Biology, 555, 63–75. [CrossRef] [Google Scholar]
  22. Charoenvit Y, Brice GT, Bacon D, Majam V, Williams J, Abot E, Ganeshan H, Sedegah M, Doolan DL, Carucci DJ, Zimmerman DH. 2004. A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrobial Agents and Chemotherapy, 48, 2455–2463. [CrossRef] [PubMed] [Google Scholar]
  23. Chimanuka B, Gabriëls M, Detaevernier MR, Plaizier-Vercammen JA. 2002. Preparation of beta-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. Journal of Pharmaceutical and Biomedical Analysis, 28, 13–22. [CrossRef] [PubMed] [Google Scholar]
  24. Chin CD, Linder V, Sia SK. 2007. Lab-on-a-chip devices for global health: past studies and future opportunities. Lab on a Chip, 7, 41–57. [CrossRef] [PubMed] [Google Scholar]
  25. Cowman AF, Baldi DL, Healer J, Mills KE, O’Donnell RA, Reed MB, Triglia T, Wickham ME, Crabb BS. 2000. Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells. FEBS Letters, 476, 84–88. [CrossRef] [PubMed] [Google Scholar]
  26. Date AA, Joshi MD, Patravale VB. 2007. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Advance Drug Delivery Reviews, 59, 505–521. [CrossRef] [Google Scholar]
  27. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America, 93, 13143–13147. [CrossRef] [PubMed] [Google Scholar]
  28. Dittrich PS, Manz A. 2006. Lab-on-a-chip: microfluidics in drug discovery. Nature Reviews Drug Discovery, 5, 210–218. [Google Scholar]
  29. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine, 344, 257–263. [CrossRef] [Google Scholar]
  30. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. New England Journal of Medicine, 365, 1073–1075. [CrossRef] [Google Scholar]
  31. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361, 455–467. [CrossRef] [PubMed] [Google Scholar]
  32. Drinnenberg IA, Weinberg DE, Xie KT, Mower JP, Wolfe KH, Fink GR, Bartel DP. 2009. RNAi in budding yeast. Science, 23, 544–550. [CrossRef] [Google Scholar]
  33. Duraisingh MT, Cowman AF. 2005. Contribution of the Pfmdr1 gene to antimalarial drug resistance. Acta Tropica, 94, 181–190. [CrossRef] [PubMed] [Google Scholar]
  34. Eijkel JCT, Van den Berg A. 2005. Nanofluidics: what is it and what can we expect from it? Microfluids and Nanofluidics, 1, 249–267. [Google Scholar]
  35. El-Ali J, Sorger PK, Jensen KF. 2006. Cells on chips. Nature, 442, 403–411. [CrossRef] [PubMed] [Google Scholar]
  36. Elbadry MA, Existe A, Victor YS, Memnon G, Fukuda M, Dame JB, Yowell CA, Okech BA. 2013. Survey of Plasmodium falciparum multidrug resistance-1 and chloroquine resistance transporter alleles in Haiti. Malaria Journal, 12, 426. [CrossRef] [PubMed] [Google Scholar]
  37. Eltayeb SE, Su Z, Shi Y, Li S, Xiao Y, Ping Q. 2013. Preparation and optimization of transferrin-modified-artemether lipid nanospheres based on the orthogonal design of emulsion formulation and physically electrostatic adsorption. International Journal of Pharmaceutics, 452, 321–332. [CrossRef] [PubMed] [Google Scholar]
  38. Enserink M. 2010. Malaria’s drug miracle in danger. Science, 328, 844–846. [CrossRef] [PubMed] [Google Scholar]
  39. Fennell BJ, Carolan S, Pettit GR, Bell A. 2003. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. Journal of Antimicrobial Chemotherapy, 51, 833–841. [CrossRef] [Google Scholar]
  40. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, Wellems TE. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Molecular Microbiology, 52, 985–997. [CrossRef] [PubMed] [Google Scholar]
  41. Fire A. 1999. RNA-triggered gene silencing. Trends in Genetics, 15, 358–363. [CrossRef] [Google Scholar]
  42. Foote SJ, Cowman AF. 1994. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Tropica, 56, 157–171. [CrossRef] [PubMed] [Google Scholar]
  43. Forrest ML, Kwon GS. 2008. Clinical developments in drug delivery nanotechnology. Advance Drug Delivery Reviews, 60, 861–862. [CrossRef] [Google Scholar]
  44. Gissot M, Briquet S, Refour P, Boschet C, Vaquero C. 2005. PfMyb1, a Plasmodium falciparum transcription factor, is required for intra-erythrocytic growth and controls key genes for cell cycle regulation. Journal of Molecular Biology, 346, 29–42. [CrossRef] [PubMed] [Google Scholar]
  45. Global report on Antimalarial Drug efficacy and Drug Resistance: World Health Organization. 2000–2010. [Google Scholar]
  46. Gosh JK, Shaool D, Guillaud P, Cicéron L, Mazier D, Kustanovich I, Shai Y, Mor A. 1997. Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. Journal of Biological Chemistry, 272, 31609–31616. [CrossRef] [Google Scholar]
  47. Goodman CD, McFadden GI. 2013. Targeting apicoplasts in malaria parasites. Expert Opinion on Therapeutic Targets, 17, 167–170. [CrossRef] [PubMed] [Google Scholar]
  48. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. 2012. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Advance Drug Delivery Reviews, 64, 316–326. [CrossRef] [Google Scholar]
  49. Gregson A, Plowe CV. 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacological Reviews, 57, 117–145. [Google Scholar]
  50. Gupta Y, Jain A, Jain SK. 2007. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. Journal of Pharmacy and Pharmacology, 59, 935–940. [CrossRef] [Google Scholar]
  51. Hastings I, Watkins WM, White NJ. 2002. Pharmacokinetic parameters affecting the evolution of drug-resistance in malaria: the role of the terminal elimination half-life. Philosophical Transactions of the Royal Society B: Biological Science, 357, 505–519. [CrossRef] [Google Scholar]
  52. Hastings IM. 2006. Complex dynamics and stability of resistance to antimalarial drugs. Parasitology, 132, 615–624. [CrossRef] [PubMed] [Google Scholar]
  53. Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, Mosnier J, Amalvict R, Fusai T, Rogier C, Pradines B. 2009. Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrobial Agents and Chemotherapy, 53, 1926–1930. [CrossRef] [PubMed] [Google Scholar]
  54. Hyde JE. 2002. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes and Infection, 4, 165–174. [CrossRef] [Google Scholar]
  55. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Das D, Phyo AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S, Koecharoen K, Nguon C, Day NP, Socheat D, White NJ. 2010. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 54, 2886–2892. [CrossRef] [PubMed] [Google Scholar]
  56. Isacchi B, Arrigucci S, La Marca G, Bergonzi MC, Vannucchi MG, Novelli A, Bilia AR. 2011. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. Journal of Liposome Research, 21, 237–244. [CrossRef] [PubMed] [Google Scholar]
  57. Jain K, Sood S, Gowthamarajan K. 2014. Lipid nanocarriers and molecular targets for malaria chemotherapy. Current Drug Targets, 15, 292–312. [CrossRef] [PubMed] [Google Scholar]
  58. Kang L, Chung BG, Langer R, Khademhosseini A. 2008. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discovery, 13, 1–13. [CrossRef] [PubMed] [Google Scholar]
  59. Kayser O, Kiderlen AF. 2003. Delivery strategies for antiparasitics. Expert Opinion on Investigational Drugs, 12, 197–207. [CrossRef] [PubMed] [Google Scholar]
  60. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrobial Agents and Chemotherapy, 44, 2100–2108. [CrossRef] [PubMed] [Google Scholar]
  61. Krishna S, Pulcini S, Moore CM, Teo B, Staines HM. 2014. Pumped up: reflections on PfATP6 as the target for artemisinins. Trends in Pharmacological Sciences, 35, 4–11. [CrossRef] [PubMed] [Google Scholar]
  62. Krugliak M, Feder R, Zolotarev VY. 2000. Antimalarial activities of Dermaseptin S4 derivatives. Antimicrobial Agents and Chemotherapy, 44, 2442–2451. [CrossRef] [PubMed] [Google Scholar]
  63. Kumar R, Adams B, Oldenburg A, Musiyenko A, Barik S. 2002. Characterisation and expression of a PP1 serine/threonine protein phosphatase (PfPP1) from the malaria parasite, Plasmodium falciparum: demonstration of its essential role using RNA interference. Malaria Journal, 1, 5. [CrossRef] [PubMed] [Google Scholar]
  64. Lagally ET, Scherer JR, Blazej RG, Toriello NM, Diep BA, Ramchandani M, Sensabaugh GF, Riley LW, Mathies RA. 2004. Integrated portable genetic analysis microsystem for pathogen/infectious disease detection. Analytical Chemistry, 76, 3162–3170. [CrossRef] [PubMed] [Google Scholar]
  65. Lasic DD, Martin FJ, Mayhew E. 1991. Stealth liposomes. Annals of Biomedical Engineering, 91, 594. [Google Scholar]
  66. Legrand P, Mosqueira V, Loiseau P, Bories C, Barratt G. 2003. Long circulating nanocapsules: interest in the treatment of severe malaria with halofantrine. Annales Pharmaceutiques Françaises, 61, 196–202. [Google Scholar]
  67. Lewis IA, Wacker M, Olszewski KL, Cobbold SA, Baska KS, Tan A, Ferdig MT, Llinás M. 2014. Metabolic QTL analysis links chloroquine resistance in Plasmodium falciparum to impaired hemoglobin catabolism. PLoS Genetics, 10, 1004085. [CrossRef] [Google Scholar]
  68. Linington RG, Gonzalez J, Ureña LD, Romero LI, Ortega-Barría E, Gerwick WH. 2007. Venturamides A and B: antimalarial constituents of the panamanian marine cyanobacterium Oscillatoria sp. Journal of Natural Products, 70, 397–400. [CrossRef] [PubMed] [Google Scholar]
  69. Londono BL, Eisele TP, Keating J, Bennett A, Chattopadhyay C, Heyliger G, Mack B, Rawson I, Vely JF, Désinor O, Krogstad DJ. 2009. Chloroquine-resistant haplotype Plasmodium falciparum parasites, Haiti. Emerging Infectious Diseases, 15, 735–740. [CrossRef] [PubMed] [Google Scholar]
  70. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 54, 62–66. [Google Scholar]
  71. MacRae JI, Maréchal E, Biot C, Botté CY. 2012. The apicoplast: a key target to cure malaria. Current Pharmaceutical Design, 18, 3490–3504. [PubMed] [Google Scholar]
  72. Malhotra P, Dasaradhi PV, Kumar A, Mohmmed A, Agrawal N, Bhatnagar RK, Chauhan VS. 2002. Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Molecular Microbiology, 45, 1245–1254. [CrossRef] [PubMed] [Google Scholar]
  73. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ, White LJ. 2009. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malaria Journal, 8, 31. [CrossRef] [PubMed] [Google Scholar]
  74. McRobert L, McConkey GA. 2002. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Molecular and Biochemical Parasitology, 119, 273–278. [CrossRef] [PubMed] [Google Scholar]
  75. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimdé AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O’Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski DP. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 45, 648–655. [CrossRef] [PubMed] [Google Scholar]
  76. Mizuno Y, Makioka A, Kawazu S, Kano S, Kawai S, Akaki M, Aikawa M, Ohtomo H. 2002. Effect of jasplakinolide on the growth, invasion, and actin cytoskeleton of Plasmodium falciparum. Parasitology Research, 88, 844–848. [CrossRef] [PubMed] [Google Scholar]
  77. Mohmmed A, Dasaradhi PV, Bhatnagar RK, Chauhan VS, Malhotra P. 2003. In vivo gene silencing in Plasmodium berghei – a mouse malaria model. Biochemical and Biophysical Research Communications, 309, 506–511. [CrossRef] [PubMed] [Google Scholar]
  78. Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. 2004. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrobial Agents of Chemotherapy, 48, 1222–1228. [CrossRef] [Google Scholar]
  79. Movellan J, Urbán P, Moles E, de la Fuente JM, Sierra T, Serrano JL, Fernàndez-Busquets X. 2014. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials, 35, 7940–7950. [CrossRef] [PubMed] [Google Scholar]
  80. Mueller AK, Hammerschmidt-Kamper C, Kaiser A. 2014. RNAi in Plasmodium. Current Pharmaceutical Design, 20, 278–283. [CrossRef] [PubMed] [Google Scholar]
  81. Myers FB, Lee LP. 2008. Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab on a Chip, 8, 2015–2031. [CrossRef] [PubMed] [Google Scholar]
  82. Nagaraj G, Uma MV, Shivayogi MS, Balaram H. 2001. Antibiotics isolated from fungi antimalarial activities of peptide. Antimicrobial Agents and Chemotherapy, 45, 145. [CrossRef] [PubMed] [Google Scholar]
  83. Newton PN, Ward S, Angus BJ. 2006. Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 184–186. [CrossRef] [PubMed] [Google Scholar]
  84. Nilanonta C, Isaka M, Kittakoop P, Palittapongarnpim P, Kamchonwongpaisan S, Pittayakhajonwut D, Tanticharoen M, et al. 2000. Antimycobacterial and antiplasmodial Cyclodepsipeptides from the insect pathogenic fungus Paecilomyces tenuipes BCC 1614. Planta Medica, 66, 756–758. [CrossRef] [PubMed] [Google Scholar]
  85. Nixon GL, Pidathala C, Shone AE, Antoine T, Fisher N, O’Neill PM, Ward SA, Biagini GA. 2013. Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era. Future Medicinal Chemistry, 5, 1573–1591. [CrossRef] [PubMed] [Google Scholar]
  86. Noedl H, Se Y, Schaecher K, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine, 359, 2619–2620. [CrossRef] [PubMed] [Google Scholar]
  87. Okombo J, Kiara SM, Rono J, Mwai L, Pole L, Ohuma E, Borrmann S, Ochola LI, Nzila A. 2010. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrobial Agents and Chemotherapy, 54, 3302–3307. [CrossRef] [PubMed] [Google Scholar]
  88. Ongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimasarn K. 2001. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian Journal of Tropical Medicine and Public Health, 32, 41–49. [Google Scholar]
  89. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Advance Drug Delivery Reviews, 60, 915–928. [CrossRef] [Google Scholar]
  90. Bloland PB. 2001. Drug resistance in malaria. World Health Organization: Geneva, WHO/CDS/CSR/DRS/2001.4. [Google Scholar]
  91. Peters W. 1987. Resistance of human malaria I, III and IV, in Chemotherapy and drug resistance in malaria, 2nd ed., Academic Press: London. p. 543–568, 593–658, 659–786. [Google Scholar]
  92. Peters W. 1990. The prevention of antimalarial drug resistance. Pharmacology Therapy, 47, 499–508. [CrossRef] [Google Scholar]
  93. Pérez-Picaso L, Velasco-Bejarano B, Aguilar-Guadarrama AB, Argotte-Ramos R, Rios MY. 2009. Antimalarial activity of ultra-short peptides. Molecules, 14, 5103–5114. [CrossRef] [PubMed] [Google Scholar]
  94. Polpanich D, Tangboriboonrat P, Elaissari A, Udomsangpetch R. 2007. Detection of malaria infection via latex agglutination assay. Analytical Chemistry, 79, 4690–4695. [CrossRef] [PubMed] [Google Scholar]
  95. Postma NS, Crommelin DJ, Eling WM, Zuidema J. 1999. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. Journal of Pharmacology and Experimental Therapeutics, 288, 114–120. [Google Scholar]
  96. Pushparaj PN, Aarthi JJ, Kumar SD, Manikandan J. 2008. RNAi and RNAa – the Yin and Yang of RNAome. Bioinformation, 2, 235–237. [CrossRef] [PubMed] [Google Scholar]
  97. Raabe CA, Sanchez CP, Randau G, Robeck T, Skryabin BV, Chinni SV, Kube M, Reinhardt R, Ng GH, Manickam R, Kuryshev VY, Lanzer M, Brosius J, Tang TH, Rozhdestvensky TS. 2010. A global view of the nonprotein-coding transcriptome in Plasmodium falciparum. Nucleic Acids Research, 38(2), 608–617. [CrossRef] [PubMed] [Google Scholar]
  98. Rautenbach M, Vlok NM, Stander M, Hoppe HC. 2007. Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. Biochimica et Biophysica Acta, 1768, 1488–1497. [CrossRef] [PubMed] [Google Scholar]
  99. Thakur RS, Sultan T, Sanyal A, Atul PK, Punia P, Das J. 2013. Mesenchymal stem cells play an important role in host protective immune responses against malaria by modulating regulatory T cells. European Journal of Immunology, 43, 2070–2077. [CrossRef] [PubMed] [Google Scholar]
  100. Robertson RT, Baratta JL, Haynes SM, Longmuir KJ. 2008. Liposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liver. Journal of Pharmaceutical Sciences, 97, 3257–3273. [CrossRef] [PubMed] [Google Scholar]
  101. Rojas-Rivero L, Gay F, Bustos MD, Ciceron L, Pichet C, Danis M, Gentilini M. 1992. Mefloquine-halofantrine cross-resistance in Plasmodium falciparum induced by intermittent mefloquine pressure. American Journal of Tropical Medicine and Hygiene, 47, 372–377. [Google Scholar]
  102. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science, 305, 1124. [CrossRef] [PubMed] [Google Scholar]
  103. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. 1991. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. Journal of Clinical Investigation, 88, 1467–1472. [CrossRef] [Google Scholar]
  104. Sabareesh V, Ranganayaki RS, Raghothama S, Bopanna MP, Balaram H, Srinivasan MC, Balaram P. 2007. Identification and characterization of a library of microheterogeneous cyclohexadepsipeptides from the fungus Isaria. Journal of Natural Products, 70, 715–729. [CrossRef] [PubMed] [Google Scholar]
  105. Saei AA, Ahmadian S. 2009. Stem cell engineering might be protective against severe malaria. Bioscience Hypothesis, 2, 48–49. [CrossRef] [Google Scholar]
  106. Sá JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE. 2009. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proceedings of the National Academy of Sciences of the United States of America, 106, 18883–18889. [CrossRef] [PubMed] [Google Scholar]
  107. Santos-Magalhães NS, Mosqueira VC. 2010. Nanotechnology applied to the treatment of malaria. Advance Drug Delivery Reviews, 62, 560–575. [CrossRef] [Google Scholar]
  108. Satimai W, Sudathip P, Vijaykadga S, Khamsiriwatchara A, Sawang S, Potithavoranan T, Sangvicheanet A, Delacollette C, Singhasivanon P, Kaewkungwal J, Lawpoolsri S. 2012. Artemisinin resistance containment project in Thailand. II: Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malaria Journal, 11, 300. [CrossRef] [PubMed] [Google Scholar]
  109. Schwentke A, Krepstakies M, Müller AK, Hammerschmidt-Kamper C, Motaal BA, Bernhard T, Hauber J, Kaiser A. 2012. In vitro and in vivo silencing of plasmodial dhs and eIF-5A genes in a putative, noncanonical RNAi-related pathway. BMC Microbiology, 12, 107. [CrossRef] [PubMed] [Google Scholar]
  110. Sharma MK, Rao VK, Agarwal GS, Rai GP, Gopalan N, Prakash S, Sharma SK, Vijayaraghavan R. 2008. Highly sensitive amperometric immunosensor for detection of Plasmodium falciparum histidine-rich protein 2 in serum of humans with malaria: comparison with a commercial kit. Journal of Clinical Microbiology, 46, 3759–3765. [CrossRef] [PubMed] [Google Scholar]
  111. Song YS, Moon S, Hulli L, Hasan SK, Kayaalp E, Demirci U. 2009. Microfluidics for cryopreservation. Lab on a Chip, 9, 1874–1881. [CrossRef] [PubMed] [Google Scholar]
  112. Stanisic DI, Barry AE, Good MF. 2013. Escaping the immune system: how the malaria parasite makes vaccine development a challenge. Trends in Parasitology, 29, 612–622. [CrossRef] [PubMed] [Google Scholar]
  113. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, Fukuda MM, Hien TT, Mayxay M, Noedl H, Nosten F, Kyaw MP, Nhien NT, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Ariey F, Mercereau-Puijalon O, Menard D, Newton PN, Khanthavong M, Hongvanthong B, Starzengruber P, Fuehrer HP, Swoboda P, Khan WA, Phyo AP, Nyunt MM, Nyunt MH, Brown TS, Adams M, Pepin CS, Bailey J, Tan JC, Ferdig MT, Clark TG, Miotto O, MacInnis B, Kwiatkowski DP, White NJ, Ringwald P, Plowe CV. 2014. Independent emergence of Plasmodium falciparum artemisinin resistance mutations in Southeast Asia. Journal of Infectious Diseases [Epub ahead of print]. [Google Scholar]
  114. Tarique M, Tabassum F, Ahmad M, Tuteja R. 2014. Plasmodium falciparum UvrD activities are downregulated by DNA-interacting compounds and its dsRNA inhibits malaria parasite growth. BMC Biochemistry, 15, 9. [CrossRef] [PubMed] [Google Scholar]
  115. Tayade NG, Nagarsenker MS. 2010. Development and evaluation of artemether parenteral microemulsion. Indian Journal of Pharmaceutical Sciences, 72, 637–640. [CrossRef] [PubMed] [Google Scholar]
  116. Thongtan J, Saenboonrueng J, Rachtawee P, Isaka M. 2006. An antimalarial tetrapeptide from the entomopathogenic fungus Hirsutella sp. BCC 1528. Journal of Natural Products, 69, 713–714. [CrossRef] [PubMed] [Google Scholar]
  117. Torrentino-Madamet M, Desplans J, Travaillé C, James Y, Parzy D. 2010. Microaerophilic respiratory metabolism of Plasmodium falciparum mitochondrion as a drug target. Current Molecular Medicine, 10, 29–46. [CrossRef] [PubMed] [Google Scholar]
  118. Tuteja R, Pradhan A, Sharma S. 2008. Plasmodium falciparum signal peptidase is regulated by phosphorylation and required for intra-erythrocytic growth. Molecular and Biochemical Parasitology, 157, 137–147. [CrossRef] [PubMed] [Google Scholar]
  119. Tuteja R, Pradhan A. 2010. Using RNA interference assay we show that PfeIF4A and PfeIF4A (PfH45) are essentially required for the growth and survival of the parasite. PfeIF4E and PfeIF4A colocalize and their double-stranded RNA inhibits Plasmodium falciparum proliferation. Communicative & Integrative Biology, 3, 611–613. [CrossRef] [PubMed] [Google Scholar]
  120. Ullu E, Tschudi C, Chakraborty T. 2004. RNA interference in protozoan parasites. Cell Microbiology, 6, 509–519. [CrossRef] [Google Scholar]
  121. Urbán P, Estelrich J, Cortés A, Fernàndez-Busquets X. 2011. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. Journal of Control Release, 151, 202–211. [CrossRef] [Google Scholar]
  122. Urban P, Valle-Delgado JJ, Mauro N, Marques J, Manfredi A, Rottmann M, et al. 2014. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. Journal of Control Release, 177, 84–95. [CrossRef] [Google Scholar]
  123. Van Tyne D, Park DJ, Schaffner SF, Neafsey DE, Angelino E, Cortese JF, Barnes KG, Rosen DM, Lukens AK, Daniels RF, Milner DA Jr, Johnson CA, Shlyakhter I, Grossman SR, Becker JS, Yamins D, Karlsson EK, Ndiaye D, Sarr O, Mboup S, Happi C, Furlotte NA, Eskin E, Kang HM, Hartl DL, Birren BW, Wiegand RC, Lander ES, Wirth DF, Volkman SK, Sabeti PC. 2011. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genetics, 7, e1001383. [CrossRef] [PubMed] [Google Scholar]
  124. Vial H, Taramelli D, Boulton IC, Ward SA, Doerig C, Chibale K. 2013. CRIMALDDI: platform technologies and novel anti-malarial drug targets. Malaria Journal, 12, 396. [CrossRef] [PubMed] [Google Scholar]
  125. Ward SA, Bray PG, Mungthin M, Hawley SR. 1995. Current views on the mechanisms of resistance to quinoline-containing drugs in Plasmodium falciparum. Annals of Tropical Medicine and Parasitology, 89, 121–124. [PubMed] [Google Scholar]
  126. Watkins WM, Mosobo M. 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 75–78. [CrossRef] [PubMed] [Google Scholar]
  127. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. 1999. More on the efficacy of antifolate antimalarial combinations in Africa. Parasitology Today, 15, 131–132. [CrossRef] [Google Scholar]
  128. Wernsdorfer WH, Payne D. 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacology Therapy, 50, 95–121. [CrossRef] [Google Scholar]
  129. Wernsdorfer WH. 1994. Epidemiology of drug resistance in malaria. Acta Tropica, 56, 143–156. [CrossRef] [PubMed] [Google Scholar]
  130. West J, Becker M, Tombrink S, Tombrink S, Manz A. 2008. Micro total analysis systems: latest achievements. Analytical Chemistry, 80, 4403–4419. [CrossRef] [PubMed] [Google Scholar]
  131. White NJ. 1999. Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society B: Biological Science, 354, 739–749. [CrossRef] [Google Scholar]
  132. WHO. 2001. Antimalarial drug combination therapy. World Health Organization: Geneva. [Google Scholar]
  133. WHO. 2006. WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills. New malaria treatment guidelines issued by WHO. Saudi Medical Journal, 27, 574–575. [PubMed] [Google Scholar]
  134. WHO. 2012. World malaria report 2012. World Health Organization: Geneva. [Google Scholar]
  135. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J. 2000. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. Journal of Infectious Diseases, 190, 1541–1546. [CrossRef] [Google Scholar]
  136. Wiwanitkit V. 2009. Alternative tools for field analysis on malarial infection: a reappraisal. Clinical Therapeutics, 160, 83–85. [Google Scholar]
  137. WHO. 1967. World Malaria Report. World Health Organization: Geneva. [Google Scholar]
  138. WHO. 2010. World Malaria Report. World Health Organization: Geneva. [Google Scholar]
  139. WHO. 2013. World Malaria Report. World Health Organization: Geneva. [Google Scholar]
  140. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. American Journal of Tropical Medicine and Hygiene, 71, 179–186. [Google Scholar]
  141. Zhang C, Xiao B, Jiang Y, Zhao Y, Li Z, Gao H, Ling Y, Wei J, Li S, Lu M, Su XZ, Cui H, Yuan J. 2014. Efficient editing of malaria parasite genome using the CRISPR/Cas9 system. Molecular Biology, 5, e01414-14. [Google Scholar]
  142. Zhang Y, Mi JY, Rui YJ, Xu YL, Wang W. 2014. Stem cell therapy for the treatment of parasitic infections: is it far away. Parasitology Research, 113, 607–612. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.